Violaine Havelange

7.7k total citations · 1 hit paper
46 papers, 1.7k citations indexed

About

Violaine Havelange is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Violaine Havelange has authored 46 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 22 papers in Molecular Biology and 16 papers in Genetics. Recurrent topics in Violaine Havelange's work include Acute Myeloid Leukemia Research (17 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers). Violaine Havelange is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers). Violaine Havelange collaborates with scholars based in Belgium, United States and France. Violaine Havelange's co-authors include Ramiro Garzon, Carlo M. Croce, Carlos Graux, Michael Andreeff, Stefano Volinia, Guido Marcucci, Gerhard Zugmaier, Albrecht Reichle, Massimiliano Bonifacio and Ralf C. Bargou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Violaine Havelange

44 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

2018 516 citations Nicola Gökbuget, Hervé Dombret et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Violaine Havelange Belgium	17	769	678	558	525	468	46	1.7k
Manoj Raghavan United Kingdom	17	734 1.0×	910 1.3×	257 0.5×	267 0.5×	308 0.7×	45	1.7k
Zuzana Zemanová Czechia	22	744 1.0×	987 1.5×	307 0.6×	235 0.4×	380 0.8×	139	1.7k
Philipp A. Greif Germany	19	718 0.9×	696 1.0×	387 0.7×	215 0.4×	227 0.5×	59	1.4k
Anna Guarini Italy	28	770 1.0×	1.1k 1.7×	536 1.0×	358 0.7×	622 1.3×	91	2.5k
Francesco Albano Italy	25	771 1.0×	1.0k 1.5×	236 0.4×	279 0.5×	322 0.7×	140	1.8k
Paula Gameiro Portugal	14	726 0.9×	1.1k 1.6×	229 0.4×	113 0.2×	798 1.7×	29	1.8k
Emmanuelle Clappier France	20	785 1.0×	807 1.2×	290 0.5×	238 0.5×	712 1.5×	46	1.7k
Y Hayashi Japan	26	926 1.2×	1.2k 1.7×	321 0.6×	237 0.5×	754 1.6×	47	2.3k
Anne E. Wiktor United States	22	547 0.7×	263 0.4×	415 0.7×	258 0.5×	130 0.3×	55	1.5k
Jessica A. Pollard United States	21	649 0.8×	1.1k 1.6×	385 0.7×	76 0.1×	493 1.1×	79	1.6k

Countries citing papers authored by Violaine Havelange

Since Specialization

Citations

This map shows the geographic impact of Violaine Havelange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Violaine Havelange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Violaine Havelange more than expected).

Fields of papers citing papers by Violaine Havelange

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Violaine Havelange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Violaine Havelange. The network helps show where Violaine Havelange may publish in the future.

Co-authorship network of co-authors of Violaine Havelange

This figure shows the co-authorship network connecting the top 25 collaborators of Violaine Havelange. A scholar is included among the top collaborators of Violaine Havelange based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Violaine Havelange. Violaine Havelange is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Claus, Melissa A., Ahmed Essaghir, Sandrine Lenglez, et al.. (2025). MiR-92a-1-5p contributes to cellular proliferation and survival in chronic myeloid leukemia and its inhibition enhances imatinib efficacy. Non-coding RNA Research. 14. 14–24. 2 indexed citations

Pötgens, Sarah A., Violaine Havelange, Fuyong Li, et al.. (2024). Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia. Haematologica. 109(10). 3194–3208. 7 indexed citations

Pötgens, Sarah A., Violaine Havelange, Fuyong Li, et al.. (2023). Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss. Clinical Nutrition. 42(11). 2214–2228. 15 indexed citations

Vainchenker, William, et al.. (2023). Recent advances in therapies for primary myelofibrosis. PubMed. 12. 23–23. 6 indexed citations

Sallman, David A., Tessa Kerre, Violaine Havelange, et al.. (2023). CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. The Lancet Haematology. 10(3). e191–e202. 67 indexed citations

Hermans, Michel P., et al.. (2023). Association between severe acute malnutrition in childhood and hematological disorders in adulthood: the Lwiro follow-up study in the Eastern Democratic Republic of the Congo. BMC Nutrition. 9(1). 128–128. 1 indexed citations

Baren, Nicolas van, Violaine Havelange, Christophe Vanderaa, et al.. (2022). Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis. Blood. 141(5). 490–502. 12 indexed citations

Devos, Timothy, et al.. (2021). Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology. 27(1). 23–31. 10 indexed citations

Essaghir, Ahmed, Sandrine Lenglez, Carlos Graux, et al.. (2020). miR‐15a‐5p and miR‐21‐5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. Journal of Cellular and Molecular Medicine. 25(1). 575–585. 33 indexed citations

10.

Huls, Gerwin, Dana Chiţu, Violaine Havelange, et al.. (2019). Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 133(13). 1457–1464. 119 indexed citations

11.

Devos, Timothy, Gregor Verhoef, Dominiek Mazure, et al.. (2019). Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. Acta Haematologica. 142(4). 197–207. 4 indexed citations

12.

Gökbuget, Nicola, Hervé Dombret, Massimiliano Bonifacio, et al.. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 131(14). 1522–1531. 516 indexed citations breakdown →

13.

Chiţu, Dana, Violaine Havelange, Mojca Jongen‐Lavrencic, et al.. (2017). Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15). Blood. 130. 463–463. 5 indexed citations

14.

Cortes, Jörge E., Jessica K. Altman, Ellen K. Ritchie, et al.. (2017). A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.. Journal of Clinical Oncology. 35(15_suppl). TPS7068–TPS7068. 8 indexed citations

15.

Vekemans, Marie‐Christiane, Catherine Lambert, Augustin Ferrant, et al.. (2015). Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab. Blood Coagulation & Fibrinolysis. 26(4). 464–466. 13 indexed citations

16.

Havelange, Violaine, Parvathi Ranganathan, Susan M. Geyer, et al.. (2014). Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 123(15). 2412–2415. 39 indexed citations

17.

Ravandi, Farhad, Ellen K. Ritchie, Hamid Sayar, et al.. (2012). VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 30(15_suppl). TPS6637–TPS6637. 5 indexed citations

18.

Havelange, Violaine & Ramiro Garzon. (2010). Micrornas: Emerging key regulators of hematopoiesis. American Journal of Hematology. 85(12). 935–942. 77 indexed citations

19.

Havelange, Violaine, Ramiro Garzon, & Carlo M. Croce. (2009). MicroRNAs: new players in acute myeloid leukaemia. British Journal of Cancer. 101(5). 743–748. 19 indexed citations

20.

Havelange, Violaine, Hélène Antoine‐Poirel, Pascale Saussoy, Eric Van Den Neste, & Augustin Ferrant. (2006). DONOR CELL LEUKEMIA DEVELOPING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA. Acta Clinica Belgica. 61(2). 82–86. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact